Helicobacter pylori Infection
Conditions
Interventions
Experimental group:Vonoprazan 20mg twice a day + Minocycline 100mg twice a day
control group:Rabeprazole 10mg twice/day + bismuth potassium citrate 220mg twice/day + amoxicillin 1000mg twice/day + clarithromycin 500mg twice/day
Sponsors
Department of Gastroenterology, Peking
University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-70 years old, male or female; (2) 13C urea breath test indicates Helicobacter pylori positive infection, and the doctor determines that the eradication of H.pylori treatment is necessary; (3) Meet the indication of Helicobacter pylori eradication (according to the Sixth National Consensus Report on Helicobacter pylori Infection Treatment); (4) Infected persons who have not previously received eradication therapy for Helicobacter pylori infection
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women; (2) Allergic to the therapeutic drugs used in the eradication programme; (3) Patients who are taking azanavir sulfate, Ripiavirin, or terphenadine; (4) Previous history of gastric or esophageal surgery; (5) Patients with severe cardiovascular and cerebrovascular diseases (including arrhythmia, bradycardia, prolonged Q-T interval, ischemic heart disease, congestive heart failure, etc.), liver and kidney insufficiency, and abnormal coagulation function; (6) uncontrolled acute disease; (7) Previous history of digestive system tumors; (8) Taking drugs such as PPI and H2 blockers that may affect the study results within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate;Adverse effects rate, ADR; | — |
Secondary
| Measure | Time frame |
|---|---|
| compliance; | — |
Countries
China
Contacts
Public ContactWeihong Wang
Department of Gastroenterology, Peking University First Hospital
Outcome results
None listed